Literature DB >> 26172291

Malaria vaccine clinical trials: what's on the horizon.

Alberto Moreno1, Chester Joyner2.   

Abstract

Significant progress toward a malaria vaccine, specifically for Plasmodium falciparum, has been made in the past few years with the completion of numerous clinical trials. Each trial has utilized a unique combination of antigens, delivery platforms, and adjuvants, which has provided the research community with a wealth of critical information to apply towards the development of next generation malaria vaccines. Despite the progress toward a P. falciparum vaccine, P. vivax vaccine research requires more momentum and additional investigations to identify novel vaccine candidates. In this review, recently completed and ongoing malaria vaccine clinical trials as well as vaccine candidates that are in the development pipeline are reviewed. Perspectives for future research using post-genomic mining, nonhuman primate models, and systems biology are also discussed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26172291      PMCID: PMC4553069          DOI: 10.1016/j.coi.2015.06.008

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  61 in total

1.  Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

Authors:  Mark E Polhemus; Alan J Magill; James F Cummings; Kent E Kester; Chris F Ockenhouse; David E Lanar; Sheetij Dutta; Arnoldo Barbosa; Lorraine Soisson; Carter L Diggs; Sally A Robinson; John D Haynes; V Ann Stewart; Lisa A Ware; Clara Brando; Urszula Krzych; Robert A Bowden; Joe D Cohen; Marie-Claude Dubois; Opokua Ofori-Anyinam; Els De-Kock; W Ripley Ballou; D Gray Heppner
Journal:  Vaccine       Date:  2007-03-26       Impact factor: 3.641

2.  Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection.

Authors:  W A Krotoski; P C Garnham; R S Bray; D M Krotoski; R Killick-Kendrick; C C Draper; G A Targett; M W Guy
Journal:  Am J Trop Med Hyg       Date:  1982-01       Impact factor: 2.345

Review 3.  Systems biological approaches to measure and understand vaccine immunity in humans.

Authors:  Shuzhao Li; Helder I Nakaya; Dmitri A Kazmin; Jason Z Oh; Bali Pulendran
Journal:  Semin Immunol       Date:  2013-06-21       Impact factor: 11.130

4.  Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Authors:  Joanne M Lumsden; Sathit Pichyangkul; Utaiwan Srichairatanakul; Kosol Yongvanitchit; Amporn Limsalakpetch; Saule Nurmukhambetova; Jennifer Klein; Sylvie Bertholet; Thomas S Vedvick; Steven G Reed; Jetsumon Sattabongkot; Jason W Bennett; Mark E Polhemus; Christian F Ockenhouse; Randall F Howard; Anjali Yadava
Journal:  Infect Immun       Date:  2011-06-20       Impact factor: 3.441

Review 5.  The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review.

Authors:  Judith E Epstein; Thomas L Richie
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

6.  Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein.

Authors:  S P Wertheimer; J W Barnwell
Journal:  Exp Parasitol       Date:  1989-11       Impact factor: 2.011

7.  Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria.

Authors:  Thomas M Clausen; Stig Christoffersen; Madeleine Dahlbäck; Annette Eva Langkilde; Kamilla E Jensen; Mafalda Resende; Mette Ø Agerbæk; Daniel Andersen; Besim Berisha; Sisse B Ditlev; Vera V Pinto; Morten A Nielsen; Thor G Theander; Sine Larsen; Ali Salanti
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

8.  Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum.

Authors:  Cécile Crosnier; Leyla Y Bustamante; S Josefin Bartholdson; Amy K Bei; Michel Theron; Makoto Uchikawa; Souleymane Mboup; Omar Ndir; Dominic P Kwiatkowski; Manoj T Duraisingh; Julian C Rayner; Gavin J Wright
Journal:  Nature       Date:  2011-11-09       Impact factor: 49.962

Review 9.  The case for a rational genome-based vaccine against malaria.

Authors:  Carla Proietti; Denise L Doolan
Journal:  Front Microbiol       Date:  2015-01-22       Impact factor: 5.640

10.  Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection.

Authors:  Matthew B Laurens; Peter Billingsley; Adam Richman; Abraham G Eappen; Matthew Adams; Tao Li; Sumana Chakravarty; Anusha Gunasekera; Christopher G Jacob; B Kim Lee Sim; Robert Edelman; Christopher V Plowe; Stephen L Hoffman; Kirsten E Lyke
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more
  8 in total

Review 1.  Systems biology of malaria explored with nonhuman primates.

Authors:  Mary R Galinski
Journal:  Malar J       Date:  2022-06-07       Impact factor: 3.469

2.  Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites.

Authors:  Myriam Arévalo-Herrera; Mary Lopez-Perez; Emmanuel Dotsey; Aarti Jain; Kelly Rubiano; Philip L Felgner; D Huw Davies; Sócrates Herrera
Journal:  PLoS Negl Trop Dis       Date:  2016-03-25

3.  Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study.

Authors:  Pilar Requena; Myriam Arévalo-Herrera; Michela Menegon; Flor E Martínez-Espinosa; Norma Padilla; Camila Bôtto-Menezes; Adriana Malheiro; Dhiraj Hans; Maria Eugenia Castellanos; Leanne Robinson; Paula Samol; Swati Kochar; Sanjay K Kochar; Dhanpat K Kochar; Meghna Desai; Sergi Sanz; Llorenç Quintó; Alfredo Mayor; Stephen Rogerson; Ivo Mueller; Carlo Severini; Hernando A Del Portillo; Azucena Bardají; Chetan C Chitnis; Clara Menéndez; Carlota Dobaño
Journal:  Front Immunol       Date:  2017-02-17       Impact factor: 7.561

Review 4.  The Search of a Malaria Vaccine: The Time for Modified Immuno-Potentiating Probes.

Authors:  José Manuel Lozano; Zully Rodríguez Parra; Salvador Hernández-Martínez; Maria Fernanda Yasnot-Acosta; Angela Patricia Rojas; Luz Stella Marín-Waldo; Juan Edilberto Rincón
Journal:  Vaccines (Basel)       Date:  2021-02-02

5.  A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Authors:  Jairo Andres Fonseca; Monica Cabrera-Mora; Elena A Kashentseva; John Paul Villegas; Alejandra Fernandez; Amelia Van Pelt; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

6.  Bacterial superglue enables easy development of efficient virus-like particle based vaccines.

Authors:  Susan Thrane; Christoph M Janitzek; Sungwa Matondo; Mafalda Resende; Tobias Gustavsson; Willem Adriaan de Jongh; Stine Clemmensen; Will Roeffen; Marga van de Vegte-Bolmer; Geert Jan van Gemert; Robert Sauerwein; John T Schiller; Morten A Nielsen; Thor G Theander; Ali Salanti; Adam F Sander
Journal:  J Nanobiotechnology       Date:  2016-04-27       Impact factor: 10.435

Review 7.  Arbovirosis and potential transmission blocking vaccines.

Authors:  Berlin Londono-Renteria; Andrea Troupin; Tonya M Colpitts
Journal:  Parasit Vectors       Date:  2016-09-23       Impact factor: 3.876

8.  A comprehensive study of epitopes and immune reactivity among Plasmodium species.

Authors:  Meenu Kalkal; Amit Kalkal; Sandeep Kumar Dhanda; Emily Das; Veena Pande; Jyoti Das
Journal:  BMC Microbiol       Date:  2022-03-11       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.